Sartorius_May21_NeutAntiMakingTheir - 21

NEUTRALIZING ANTIBODIES MAKING THEIR MARK IN NEXT WAVE OF BIOLOGICS

Translational Medicine, in an article titled,

those antibodies specifically targeted

" Preexisting immunity shapes distinct

non-neutralizing sites, " said Haley Dugan,

antibody landscapes after influenza virus

co-first author of the study and a PhD

infection and vaccination in humans. "

candidate in immunology. " When we tested

The researchers compared antibodies

these same antibodies in mice, they weren't

produced by individuals after influenza

able to protect them from being infected

infection or vaccination. They found that

with influenza. "

infection-induced antibodies reacted to

In contrast, the researchers found that

non-neutralizing epitopes of influenza virus,
whereas vaccination-induced antibodies
reacted to neutralizing epitopes.
The team found that most of the initial
antibodies stimulated after both influenza
infections and influenza vaccinations
came from old B cells, indicating the
immune system's memory plays a major

" This study provides a major
framework for understanding
how pre-existing immunity
shapes protective antibody
responses to influenza in
humans, "

role in how the body responds early on

	

to a viral infection. These antibodies

-Patrick Wilson, PhD,
		 University of Chicago

displayed higher reactivity toward strains
of influenza that circulated during an

influenza vaccinations boost antibodies

individual's childhood compared to more

that tended to target conserved yet

recent strains.

neutralizing regions of the virus, which

" Most interestingly, we found that people

suggests vaccinations can draw upon

who were actively sick with influenza had

pre-existing immunity to prompt more

old antibodies that predominantly targeted

protective responses. Vaccinated individuals

parts of the virus that don't change-but

also generated many antibodies that
targeted new and mutated regions on the

Developing
Ne
Therapeutic xt generation
Antibodies

ADDITIONAL CONTENT
Infographic:
Developing Next Generation
Therapeutic Antibodies

Therapeutic
antibodies
are
hematologi
c cancers and one of most successful
immunothe
specificity
solid tumor
and safety
rapy strate
s. The succe
due to innov
gies for
ss of this class
ative techn
of drugs stems the treatment of both
ical advances
from the promi
in antibody
se of
engineering
and developme better
With
nt.

over 100 appr
oved antib
fastest grow
ody drugs,
ing class of
antibodies
drugs
are the

Next Gene

virus, suggesting these vaccine-induced
antibodies are more adaptable.
Immune system memory ensures a

ration Antib

odies

Bi- & Multi

-Specific Antib
odies
The developme
nt or progr
more than
ession of
one signal
ing pathway, a disease typically involv
targets may
theref
es
exist. Bi- and
recognize
multi-specifi ore multiple therapeutic
two
c
antigen-reco or more different target antibodies are design
ed to
gnizing eleme
s by comb
promise for
ining multip
nts
into a single
cancer immu
le
molecule,
notherapy.
showing
Antibody-D

rapid and specific response to previously

rug Conju

gates

Antibody-d
rug conjugates
with biolog
(ADCs) comb
ically
ine mono
targeted chem active or cytotoxic
compounds clonal antibodies
otherapeutic
to produce
antibody to
agents. After
highly
tumor cells,
the conjugated selective binding
the cell causin
of the
g tumor cell
compound
death.
is released
into
Nanobodie

s

Nanobodie
s are modifi
ed single antige
(VHH). They
are highly
n-binding
stable, solub
of reach of
variable doma
full-length
le and bind
in
antibodies.
targets that
currently in
Bi-specific
developme
nanobodies are out
nt.
are

Addressing
the Challe
nges of
Traditional
Methods

drug
linker

GENengnews.com

| 21


https://www.sartorius.com/en/pr/mab/tn-mab-next-gen-abs http://www.GENengnews.com

Sartorius_May21_NeutAntiMakingTheir

Table of Contents for the Digital Edition of Sartorius_May21_NeutAntiMakingTheir

Contents
Sartorius_May21_NeutAntiMakingTheir - 1
Sartorius_May21_NeutAntiMakingTheir - 2
Sartorius_May21_NeutAntiMakingTheir - 3
Sartorius_May21_NeutAntiMakingTheir - Contents
Sartorius_May21_NeutAntiMakingTheir - 5
Sartorius_May21_NeutAntiMakingTheir - 6
Sartorius_May21_NeutAntiMakingTheir - 7
Sartorius_May21_NeutAntiMakingTheir - 8
Sartorius_May21_NeutAntiMakingTheir - 9
Sartorius_May21_NeutAntiMakingTheir - 10
Sartorius_May21_NeutAntiMakingTheir - 11
Sartorius_May21_NeutAntiMakingTheir - 12
Sartorius_May21_NeutAntiMakingTheir - 13
Sartorius_May21_NeutAntiMakingTheir - 14
Sartorius_May21_NeutAntiMakingTheir - 15
Sartorius_May21_NeutAntiMakingTheir - 16
Sartorius_May21_NeutAntiMakingTheir - 17
Sartorius_May21_NeutAntiMakingTheir - 18
Sartorius_May21_NeutAntiMakingTheir - 19
Sartorius_May21_NeutAntiMakingTheir - 20
Sartorius_May21_NeutAntiMakingTheir - 21
Sartorius_May21_NeutAntiMakingTheir - 22
Sartorius_May21_NeutAntiMakingTheir - 23
Sartorius_May21_NeutAntiMakingTheir - 24
Sartorius_May21_NeutAntiMakingTheir - 25
Sartorius_May21_NeutAntiMakingTheir - 26
Sartorius_May21_NeutAntiMakingTheir - 27
Sartorius_May21_NeutAntiMakingTheir - 28
Sartorius_May21_NeutAntiMakingTheir - 29
Sartorius_May21_NeutAntiMakingTheir - 30
Sartorius_May21_NeutAntiMakingTheir - 31
Sartorius_May21_NeutAntiMakingTheir - 32
Sartorius_May21_NeutAntiMakingTheir - 33
Sartorius_May21_NeutAntiMakingTheir - 34
Sartorius_May21_NeutAntiMakingTheir - 35
Sartorius_May21_NeutAntiMakingTheir - 36
Sartorius_May21_NeutAntiMakingTheir - 37
Sartorius_May21_NeutAntiMakingTheir - 38
Sartorius_May21_NeutAntiMakingTheir - 39
Sartorius_May21_NeutAntiMakingTheir - 40
Sartorius_May21_NeutAntiMakingTheir - 41
Sartorius_May21_NeutAntiMakingTheir - 42
https://www.nxtbookmedia.com